방사선의학 웹진

바로가기  >

Abstract

PURPOSE:

This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and NK-cell lymphomas.

MATERIALS AND METHODS:

Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT.

RESULTS:

Patients with responsive disease underwent upfront ASCT (TBI: n=16, non-TBI: n=29) whereas patients with refractory disease (TBI: n=9, non-TBI: n=12) or relapsed disease (TBI: n=13, non-TBI: n=19, Figure 1) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0-7) in both groups. No significant difference in100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival, however the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than those who showed partial response.

CONCLUSIONS:

TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas. 

Author information

Maeng CH1, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.​

1Division of Hemato-Oncology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.

2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

4Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

5Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

6Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

7Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.